Study of new drug NDI-219216 for advanced solid tumors
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are fully active or only slightly limited in daily activities (ECOG score 0 or 1).
- Your cancer has spread and cannot be removed with surgery, and standard treatments no longer work or are not available for you.
- You have at least one tumor that can be measured on scans (this is not required for the first part of the study).
- Your blood counts, organ function (liver, kidneys, etc.), and heart function are adequate.
- Side effects from previous treatments have mostly resolved (except for hair loss, tiredness, or nerve damage).
- You do not have serious heart disease, WRN syndrome, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug that may help people with advanced solid tumors that have not responded to other treatments. The drug is given as an injection and aims to stop cancer growth.
This trial tests a new oral drug (CS231295) for people with advanced solid tumors who have run out of standard options. It aims to see how safe the drug is and how well it controls the cancer, and may slow tumor growth. You must be in reasonably good health with adequate organ function.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
Hear when a new MSI-H Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.